Navigation Links
International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
Date:3/20/2008

otrexate achieved at least a 50% (ACR50) reduction in symptoms compared to 10.8% of patients receiving placebo and methotrexate; ACR70 was achieved in 22% of the treatment group versus 2% in the control group. A rapid decrease in disease activity (DAS28)(2) was seen as early as two weeks in a greater proportion of patients treated with ACTEMRA plus methotrexate, with 27.5% achieving DAS28 less than or equal to 2.6 by 24 weeks.

Additionally, results showed that 80% of patients in the ACTEMRA (8mg/kg) plus methotrexate group responded with moderate to good improvements in RA symptoms, according to the EULAR response criteria(3), compared with 35% for those treated with placebo and methotrexate at 24 weeks. ACTEMRA was generally well tolerated; the most common adverse events reported more frequently in the ACTEMRA arms of the OPTION trial were upper respiratory tract infection, nasopharyngitis and headache.

The OPTION trial also assessed physical function and quality-of-life at baseline and every four weeks thereafter. Patients receiving ACTEMRA achieved significantly greater improvement in areas of fatigue and mental function at 24 weeks, and achieved normal levels of hemoglobin and C-reactive protein (CRP), a marker of inflammation due to RA, compared with patients receiving placebo plus methotrexate.

"We are very encouraged by the findings of the study as they further establish the role of ACTEMRA and its unique blockade of IL-6 receptors as a potential new biologic treatment option for patients with RA," said Lars Birgerson, M.D., Ph.D, Vice President, Global Head Medical Affairs, Roche.

About ACTEMRA(TM) (tocilizumab)

ACTEMRA is the first humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody. Studies suggest that reducing the activity of IL-6, one of several key cytokines involved in the inflammatory process, may reduce inflammation of the joints and relieve certain systemic effects of RA. The extensive clinical
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to ... as Vice President of Chemistry and Biochemistry. Scott joins the ... AstraZeneca Pharmaceuticals, and Amgen throughout the course of his ... "Scott is a nationally recognized thought leader ...
(Date:1/22/2015)...  ResMed Inc. (NYSE: RMD ) today announced results ... quarter was $423.0 million, a 10 percent increase compared to ... on a constant currency basis). Net income was $91.2 million, ... December 31, 2013. Diluted earnings per share for the quarter ...
(Date:1/22/2015)... Jan. 22, 2015  Amgen (NASDAQ: AMGN ) today announced ... financial results on Tuesday, Jan. 27, 2015, after the close of ... conference call with the investment community at 2 p.m. PT. Participating ... , chairman and chief executive officer, and other members of Amgen,s ...
Breaking Medicine Technology:BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... (OTCPK: SNDY) is pleased to announce that the Company ... and sales of its high quality instruments for the ... 2011, Solos Endoscopy consummated agreements, which resulted in the ... The signed settlement agreement and new consulting agreement resulted ...
... Inc. (Nasdaq: MSHL ), an oncology company ... cancer metabolism, announced today that it has reached a ... sell common stock in a private placement for gross ... of the offering, through the sale of approximately 1.94 ...
Cached Medicine Technology:Solos Endoscopy, Inc. is Primed for Growth in 2012 2Solos Endoscopy, Inc. is Primed for Growth in 2012 3Marshall Edwards Adds $2 Million in Private Placement 2Marshall Edwards Adds $2 Million in Private Placement 3
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
(Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... effective ways to control weight , , FRIDAY, Dec. 26 (HealthDay ... suppressing appetite, according to a U.K. study. , The ... types of sessions. In one, they ran for 60 minutes ... another, they did 90 minutes of weight lifting and then ...
... Most women expressed satisfaction with process, but long-term data lacking, ... who choose to donate eggs to help infertile couples should ... the first study to examine the long-term effects of donation ... is available to assess whether donating eggs when young has ...
... to date and avoid local dangers, expert advises , , ... sunnier climes this winter, kids in tow? , If ... advises an expert. , "The most common infectious ... of the world may result from exposure to contaminated ...
... basic safety rules should help keep celebrants safe , , ... the holidays, tens of thousands of Americans have to ... injuries and illnesses. That includes about 11,000 people with ... president of the American College of Emergency Physicians. ...
... practice and center for sound sleep in the Midwest is warning ... to a energy-robbing and dangerous disease known as sleep apnea. ... while sleeping. , ... Bloomington, Ind. (PRWEB) December 25, ...
... in children and adolescents should be recognized and treated ... disorders and depression, says a nationally recognized child psychiatrist ... appearing in the Dec. 25 issue of New ... of psychiatry and pediatrics at UT Southwestern, urges awareness ...
Cached Medicine News:Health News:Vigorous Treadmill Workout Curbs Appetite Hormones 2Health News:Risks and Benefits of Egg Donation Reported 2Health News:Risks and Benefits of Egg Donation Reported 3Health News:Consider Kids' Health on Tropical Trips 2Health News:How to Avoid a Holiday Trip to the ER 2Health News:Holiday Weight Gain May Contribute to Sleep Apnea Extra Pounds May Produce Severe Problems for Adults 2Health News:Childhood anxiety disorders can and should be treated, according to UT Southwestern national expert 2
1.5 mm inner cutting edge....
Phaco chopper & iris retractor 2 mm cutting edge....
Round handle dull finish. For right handed surgeon....
Cross action, round handle, maximum opening 2.8 mm....
Medicine Products: